CAI 8-K
Caris Life Sciences, Inc. (CAI)
8-K
2025-08-12
For: 2025-08-12
View Original
Added on
April 08, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________
FORM 8-K
_______________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 12, 2025
| (Exact name of registrant as specified in its charter) | ||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
| (Address of principal executive offices) | (Zip Code) | |||||||
Registrant’s telephone number, including area code: (866 ) 771-8946
Not Applicable
(Former name or former address, if changed since last report)
_______________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions :
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 12, 2025, Caris Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein solely for purposes of this Item 2.02 disclosure.
The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |||||||
| 99.1 | ||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 12, 2025 | ||||||||
| CARIS LIFE SCIENCES, INC. | ||||||||
| By: | /s/ Luke Power | |||||||
| Name: | Luke Power | |||||||
| Title: | Senior Vice President, Chief Financial Officer and Chief Accounting Officer | |||||||
Exhibit 99.1
Caris Life Sciences Reports Second Quarter 2025 Financial Results
IRVING, Texas, August 12, 2025— Caris Life Sciences, Inc. (Nasdaq: CAI), a leading, patient centric, next-generation AI TechBio company, today reported financial results for the quarter ended June 30, 2025.
Second Quarter 2025 Financial Highlights
•Reported total revenue of $181.4 million, an increase of 81.3% over the corresponding prior year period.
•Completed 50,032 clinical therapy selection cases, an increase of 22.0% over corresponding prior year period.
•Reported gross margin of 62.7%, a 2,514 bps improvement over corresponding prior year period.
•Reported net loss of $71.8 million, including $37.1 million of one-time expense associated with the conversion of redeemable convertible preferred stock, warrants and convertible notes from the initial public offering.
•Achieved positive Adjusted EBITDA of $16.7 million.
•Achieved positive net cash flow from operating activities of $7.3 million, and positive free cash flow of $5.9 million.
“Our second quarter results show the strength of our comprehensive approach and we look forward to continuing to build on this momentum into the second half of 2025,” said David D. Halbert, Founder, Chairman and CEO of Caris Life Sciences.
Recent Operating Highlights
•Surpassed 900,000+ profiles and 600,000+ total matched profiles.
◦529,000+ Whole Exome and 580,000+ Whole Transcriptome profiles.
•Welcomed LSU LCMC Health Cancer Center as the 97th member of the Caris Precision Oncology Alliance.
•Published landmark Caris Assure platform paper:
◦Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors
•Published a study evaluating the largest real-world cohort of tissue-agnostic indications:
◦Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals
•Published original data in the New England Journal of Medicine independently validating findings on tumor-infiltrating clonal hematopoiesis (TI-CH).
•Published manuscript on development and validation of proprietary GPSai.
◦GPSai: A clinically validated AI tool for tissue of origin prediction during routine tumor profiling
•Raised $159.4 million in net proceeds from the pre-IPO financing on April 1, 2025 and $519.5 million in net proceeds from initial public offering in June 2025.
Second Quarter 2025 Summary Financial Results
(amounts in thousands, except case volume, average selling price (“ASP”) and per share data) | |||||||||||||||||||||||
| Q2 2025 | Q2 2024 | % Change Y/Y | |||||||||||||||||||||
Total revenue | $ | 181,398 | $ | 100,049 | 81.3 | % | |||||||||||||||||
Molecular profiling services | 162,924 | 87,656 | 85.9 | % | |||||||||||||||||||
Pharma research & developmental services | 18,474 | 12,393 | 49.1 | % | |||||||||||||||||||
Total clinical case volume | 50,032 | 40,998 | 22.0 | % | |||||||||||||||||||
MI Profile for therapy selection volume | 42,886 | 36,426 | 17.7 | % | |||||||||||||||||||
Caris Assure for therapy selection volume | 7,146 | 4,572 | 56.3 | % | |||||||||||||||||||
Total clinical ASP | $ | 3,256 | $ | 2,138 | 52.3 | % | |||||||||||||||||
MI Profile for therapy selection ASP | 3,379 | 2,207 | 53.1 | % | |||||||||||||||||||
Caris Assure for therapy selection ASP | 2,519 | 1,587 | 58.7 | % | |||||||||||||||||||
| Total gross margin | 62.7 | % | 37.5 | % | 25.2 | % | |||||||||||||||||
Total operating expenses | $ | 131,674 | $ | 104,565 | 25.9 | % | |||||||||||||||||
Total loss from operations | $ | (17,989) | $ | (67,011) | 73.2 | % | |||||||||||||||||
Net loss | $ | (71,790) | $ | (66,186) | (8.5) | % | |||||||||||||||||
Net loss per share attributable to common shareholders, basic and diluted | $ | (7.97) | $ | (2.54) | (213.8) | % | |||||||||||||||||
| Net cash provided by (used in) operating activities | $ | 7,288 | $ | (62,926) | 111.6 | % | |||||||||||||||||
Non-GAAP measures(1) | |||||||||||||||||||||||
| Adjusted EBITDA | $ | 16,713 | $ | (50,916) | 132.8 | % | |||||||||||||||||
Free cash flow | $ | 5,902 | $ | (65,514) | 109.0 | % | |||||||||||||||||
Consolidated balance sheet data | June 30, 2025 | December 31, 2024 | Change | ||||||||||||||||||||
Cash, cash equivalents, restricted cash and marketable securities | $ | 724,936 | $ | 70,229 | $ | 654,707 | |||||||||||||||||
| Total outstanding debt, net of debt discounts | $ | 373,706 | $ | 379,528 | $ | (5,822) | |||||||||||||||||
________________________________
(1) See “Non-GAAP Measures” below.
Second Quarter 2025 Financial Results
Total revenue was $181.4 million for the three months ended June 30, 2025, compared to $100.0 million for the three months ended June 30, 2024, an increase of $81.3 million, or 81.3%.
The increase in total revenue was driven primarily by an 85.9% growth in molecular profiling services revenue, which was $162.9 million for the three months ended June 30, 2025, compared to $87.7 million for the three months ended June 30, 2024. The increase in molecular profiling services revenue was primarily driven by an increase in total clinical case volume and ASP improvements across both therapy selection solutions.
Gross profit, calculated as total revenue less cost of services, for the three months ended June 30, 2025 and 2024, was $113.7 million and $37.6 million, respectively, representing a gross margin of 62.7% and 37.5%, respectively.
Operating expenses were $131.7 million for the three months ended June 30, 2025, compared to $104.6 million for the three months ended June 30, 2024, an increase of $27.1 million, or 25.9%. The increase was primarily driven by increased stock-based compensation expense and headcount-related costs.
Net loss was $71.8 million for the three months ended June 30, 2025, which includes $37.1 million one-time expense associated with the conversion of redeemable convertible preferred stock, warrants and convertible notes from the initial public offering, as compared to $66.2 million for the three months ended June 30, 2024. Net loss per share attributable to common shareholders, basic and diluted which includes a one-time deemed dividend of $384.4 million and one-time adjustments of redeemable convertible stock to redemption value of $61.0 million, was $7.97 per share for the three months ended June 30, 2025, as compared to $2.54 per share for the three months ended June 30, 2024.
Net cash provided by operating activities was $7.3 million for the three months ended June 30, 2025, as compared to net cash used in operating activities of $62.9 million for the three months ended June 30, 2024, a 111.6% improvement. The improvement was driven by improved reimbursement from molecular profiling services, including one-time catch up payments of $35.6 million related to first quarter 2025 MI Cancer seek cases.
2025 Financial Outlook and Guidance
Caris Life Sciences expects full year 2025 revenue to be in the range of $675.0 million to $685.0 million, representing growth of 64% to 66% compared to full year 2024. Clinical therapy selection volume is expected to be in the growth range of 19% to 21% compared to full year 2024.
Conference Call Information
| Event: | Caris Second Quarter 2025 Financial Results Conference Call | |||||||
| Date: | Tuesday, August 12, 2025 | |||||||
| Time: | 3:30 p.m. CT (4:30 p.m. ET) | |||||||
| Webcast Link: | https://edge.media-server.com/mmc/p/hfsyg967 | |||||||
Accompanying materials will be posted on our investor relations website at https://investor.carislifesciences.com prior to the conference call. A replay of the conference call will be available on our investor relations website shortly after the conclusion of the call.
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
We intend to use the investor page of our website, https://investor.carislifesciences.com, as a distribution channel of material information about the Company and for complying with our disclosure obligations under Regulation FD. The information we post on our investor webpage may be deemed material. Accordingly, investors should subscribe to our investor alerts, in addition to following our press releases, SEC filings, public conference calls and webcasts.
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “potential,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or similar expressions.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, validation and timing of future solutions; commercial market acceptance for our solutions and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our substantial indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” and elsewhere in the prospectus filed with the Securities and Exchange Commission on June 20, 2025 in connection with our initial public offering, as updated in our Quarterly Report on Form 10-Q filed on or about August 12, 2025, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.
Non-GAAP Measures
We use Adjusted EBITDA and free cash flow, financial measures not calculated in accordance with generally accepted accounting principles in the United States (“GAAP”), to supplement our condensed consolidated financial statements, which are presented in accordance with GAAP. We believe the non-GAAP financial measures we use, are useful in evaluating our performance and liquidity. Our non-GAAP financial measures have limitations as analytical tools, however, and you should not consider them in isolation or as substitutes for analysis of our results as reported under GAAP. Other companies, including other companies in our industry, may not use these measures or may calculate these measures differently than as presented herein, limiting their usefulness as comparative measures.
We define Adjusted EBITDA as net loss, adjusted to exclude interest income, interest expense, changes in fair value of financial instruments, other expense, net, the provision for (benefit from) income taxes, depreciation and amortization, and stock-based compensation expense. We use Adjusted EBITDA in conjunction with GAAP measures as part of our overall assessment of our performance, including the preparation of our annual operating budget and quarterly forecasts, to evaluate the effectiveness of our business strategies, and to communicate with our board of directors concerning our financial performance. We believe Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and board of directors. Adjusted EBITDA provides a useful measure for period-to-period comparisons of our business, as it removes the effect of certain non-cash expenses and certain variable charges.
We define free cash flow as net cash used in operating activities less purchases of property and equipment. We believe free cash flow is a useful measure of liquidity that provides an additional basis for assessing our ability to generate cash. A reconciliation of the non-GAAP financial measures used in this press release to the respective comparable GAAP financial measures, can be found below.
Caris Life Sciences Media:
Corporate Communications
214.294.5606
Investor Relations:
Narendra Chokshi
Senior Vice President, Corporate Development
917.689.3511
Caris Life Sciences, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(unaudited)
| (amounts in thousands, except share and per share data) | Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
| Revenue: | |||||||||||||||||||||||
| Molecular profiling services | $ | 162,924 | $ | 87,656 | $ | 277,006 | $ | 160,890 | |||||||||||||||
| Pharma research and development services | 18,474 | 12,393 | 25,308 | 19,837 | |||||||||||||||||||
| Total revenue | 181,398 | 100,049 | 302,314 | 180,727 | |||||||||||||||||||
| Costs and operating expenses: | |||||||||||||||||||||||
| Cost of Services - Molecular profiling services | 65,321 | 59,431 | 126,215 | 112,324 | |||||||||||||||||||
| Cost of Services - Pharma research and development services | 2,392 | 3,064 | 5,350 | 4,732 | |||||||||||||||||||
| Selling and marketing expense | 42,260 | 38,710 | 82,089 | 78,319 | |||||||||||||||||||
General and administrative expense | 64,367 | 41,068 | 116,486 | 85,422 | |||||||||||||||||||
| Research and development expense | 25,047 | 24,787 | 48,114 | 59,164 | |||||||||||||||||||
| Total costs and operating expenses | 199,387 | 167,060 | 378,254 | 339,961 | |||||||||||||||||||
| Loss from operations | (17,989) | (67,011) | (75,940) | (159,234) | |||||||||||||||||||
| Other income (expense), net: | |||||||||||||||||||||||
| Interest income | 1,618 | 2,640 | 2,121 | 4,408 | |||||||||||||||||||
| Interest expense | (19,208) | (13,674) | (31,990) | (22,964) | |||||||||||||||||||
| Changes in fair value of financial instruments | (17,870) | 12,000 | (50,203) | 936 | |||||||||||||||||||
| Other expense, net | (18,341) | (141) | (18,358) | (360) | |||||||||||||||||||
| Total other income (expense), net | (53,801) | 825 | (98,430) | (17,980) | |||||||||||||||||||
| Loss before income taxes and provision for income taxes | (71,790) | (66,186) | (174,370) | (177,214) | |||||||||||||||||||
| Provision for income taxes | — | — | — | — | |||||||||||||||||||
| Net loss | (71,790) | (66,186) | (174,370) | (177,214) | |||||||||||||||||||
| Other comprehensive income, net of tax: | |||||||||||||||||||||||
| Unrealized gain on available-for-sale securities | — | — | — | 7 | |||||||||||||||||||
| Foreign currency translation adjustments | 424 | 92 | 459 | 100 | |||||||||||||||||||
| Comprehensive loss | (71,366) | (66,094) | (173,911) | (177,107) | |||||||||||||||||||
| Net loss attributable to common shareholders: | |||||||||||||||||||||||
| Net loss | (71,790) | (66,186) | (174,370) | (177,214) | |||||||||||||||||||
| Deemed dividend from Series D redeemable convertible preferred stock | (384,436) | — | (384,436) | — | |||||||||||||||||||
| Adjustments of redeemable convertible preferred stock to redemption value | (60,971) | (23,594) | (85,433) | (46,707) | |||||||||||||||||||
| Net loss attributable to common shareholders | $ | (517,197) | $ | (89,780) | $ | (644,239) | $ | (223,921) | |||||||||||||||
| Net loss per share attributable to common shareholders, basic and diluted | $ | (7.97) | $ | (2.54) | $ | (12.80) | $ | (6.34) | |||||||||||||||
| Weighted-average shares used in computing net loss per share attributable to common shareholders, basic and diluted | 64,918,988 | 35,371,424 | 50,348,947 | 35,342,180 | |||||||||||||||||||
Caris Life Sciences, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
| (amounts in thousands, except share data) | As of June 30, | As of December 31, | |||||||||
| 2025 | 2024 | ||||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash, cash equivalents, and restricted cash | $ | 720,444 | $ | 65,442 | |||||||
| Short-term marketable securities | 2,249 | 2,201 | |||||||||
| Accounts receivable | 50,889 | 88,244 | |||||||||
| Supplies | 40,613 | 39,572 | |||||||||
| Prepaid expenses and other current assets | 19,124 | 20,270 | |||||||||
| Total current assets | 833,319 | 215,729 | |||||||||
| Property and equipment, net | 61,315 | 67,817 | |||||||||
| Goodwill | 19,344 | 19,344 | |||||||||
| Other assets | 41,080 | 40,844 | |||||||||
| Total assets | $ | 955,058 | $ | 343,734 | |||||||
| Liabilities, Redeemable Convertible Preferred Stock, and Shareholders' Equity (Deficit) | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 28,728 | $ | 27,791 | |||||||
| Accrued expenses and other current liabilities | 61,357 | 77,542 | |||||||||
| Current portion of indebtedness | 95 | 60,090 | |||||||||
| Total current liabilities | 90,180 | 165,423 | |||||||||
| Long-term indebtedness, net of debt discounts | 373,611 | 319,438 | |||||||||
| Warrant liabilities | — | 91,642 | |||||||||
| Other long-term liabilities | 38,363 | 44,418 | |||||||||
| Total liabilities | 502,154 | 620,921 | |||||||||
Commitments and contingencies | |||||||||||
| Redeemable convertible preferred stock: | |||||||||||
Series A preferred stock, par value $0.001: no and 490,000,000 shares authorized as of June 30, 2025 and December 31, 2024; no and 485,795,293 shares issued and outstanding as of June 30, 2025 and December 31, 2024; and $296,335 aggregate liquidation preference as of December 31, 2024 | — | 709,261 | |||||||||
Series B preferred stock, par value $0.001: no and 30,000,000 shares authorized as of June 30, 2025 and December 31, 2024; no and 29,629,630 shares issued and outstanding as of June 30, 2025 and December 31, 2024; and $16,000 aggregate liquidation preference as of December 31, 2024 | — | 42,963 | |||||||||
Series C preferred stock, par value $0.001: no and 142,000,000 shares authorized as of June 30, 2025 and December 31, 2024; no and 116,200,835 shares issued and outstanding as of June 30, 2025 and December 31, 2024; $408,715 aggregate liquidation preference as of December 31, 2024 | — | 408,715 | |||||||||
Series D preferred stock, par value $0.001: no and 102,600,000 shares authorized as of June 30, 2025 and December 31, 2024; no and 102,516,283 shares issued and outstanding as of June 30, 2025 and December 31, 2024; and $1,060,712 aggregate liquidation preference as of December 31, 2024 | — | 1,060,712 | |||||||||
| Redeemable convertible preferred stock | — | 2,221,651 | |||||||||
| Shareholders' equity (deficit): | |||||||||||
Preferred stock, $0.001 par value per share; 100,000,000 and no shares authorized as of June 30, 2025 and December 31, 2024, respectively; no shares issued and outstanding as of June 30, 2025 and December 31, 2024 | — | — | |||||||||
Common stock $0.001 par value; 2,800,000,000 and 1,150,000,000 shares authorized as of June 30, 2025 and December 31, 2024, respectively; 282,711,176 and 36,686,819 shares issued as of June 30, 2025 and December 31, 2024, respectively; 281,090,538 and 36,504,319 shares outstanding as of June 30, 2025 and December 31, 2024, respectively; shares issued and outstanding include 43,605 and 662,000 unvested shares subject to repurchase as of June 30, 2025 and December 31, 2024, respectively | 282 | 38 | |||||||||
Treasury stock at cost, 1,620,638 and 182,500 shares of common stock as of June 30, 2025 and December 31, 2024, respectively | (16,917) | (330) | |||||||||
| Additional paid-in capital | 3,123,888 | — | |||||||||
Related party promissory note receivable | — | (26,456) | |||||||||
| Accumulated deficit | (2,655,018) | (2,472,300) | |||||||||
| Accumulated other comprehensive income | 669 | 210 | |||||||||
| Total shareholders' equity (deficit) | 452,904 | (2,498,838) | |||||||||
| Total liabilities, redeemable convertible preferred stock, and shareholders' equity (deficit) | $ | 955,058 | $ | 343,734 | |||||||
Caris Life Sciences, Inc.
Condensed Consolidated Statement of Cash Flows
(unaudited)
| (amounts in thousands) | Six Months Ended June 30, | ||||||||||
| 2025 | 2024 | ||||||||||
| Cash flows from operating activities | |||||||||||
| Net loss | $ | (174,370) | $ | (177,214) | |||||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||||
| Depreciation and amortization | 13,454 | 29,315 | |||||||||
| Stock-based compensation expense | 42,984 | 8,943 | |||||||||
| Non-cash operating lease expense | 2,936 | 2,888 | |||||||||
| Amortization of debt discounts | 9,700 | 3,322 | |||||||||
| Changes in fair value of financial instruments | 50,203 | (937) | |||||||||
| Loss on debt extinguishment | 17,930 | — | |||||||||
| Other | 1,231 | 2,133 | |||||||||
| Changes in operating assets and liabilities: | |||||||||||
| Accounts receivable | 37,040 | (16,904) | |||||||||
| Supplies | (2,621) | 7,504 | |||||||||
| Prepaid expenses and other current assets | (2,265) | (1,383) | |||||||||
| Other assets | 334 | 430 | |||||||||
| Accounts payable | (1,925) | 2,623 | |||||||||
| Accrued expenses and other liabilities | (18,681) | 2,429 | |||||||||
| Net cash used in operating activities | (24,050) | (136,851) | |||||||||
| Cash flows from investing activities | |||||||||||
| Maturities of marketable securities | — | 61,376 | |||||||||
| Purchases of property and equipment | (4,075) | (4,326) | |||||||||
| Net cash provided by (used in) investing activities | (4,075) | 57,050 | |||||||||
| Cash flows from financing activities | |||||||||||
| Payments made on finance lease obligations | (44) | (110) | |||||||||
| Proceeds from exercise of stock options | 2,624 | 603 | |||||||||
| Payment of taxes withheld from net settlement of exercised options | (1,658) | — | |||||||||
| Payment of deferred offering costs | (2,045) | (492) | |||||||||
| Proceeds from the 2023 term loan, net of issuance costs | — | 199,978 | |||||||||
| Purchase of treasury stock | (22) | — | |||||||||
| Issuance of Series E Preferred Stock, net of issuance costs | 87,637 | — | |||||||||
| Issuance of Series F Preferred Stock, net of issuance costs | 33,601 | — | |||||||||
| Issuance of the 2025 Convertible Notes, net of issuance costs | 27,865 | — | |||||||||
| Issuance of the 2025 Warrants | 10,270 | — | |||||||||
| Payments from 2023 term loan amendment fee | (4,000) | — | |||||||||
| Proceeds from initial public offering, net of underwriting discounts and commissions | 528,459 | — | |||||||||
| Net cash provided by financing activities | 682,687 | 199,979 | |||||||||
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 97 | 13 | |||||||||
| Net increase in cash, cash equivalents, and restricted cash | 654,659 | 120,191 | |||||||||
| Cash, cash equivalents, and restricted cash at beginning of period | 68,028 | 60,007 | |||||||||
| Cash, cash equivalents, and restricted cash at end of period | $ | 722,687 | $ | 180,198 | |||||||
Reconciliation of GAAP Net Loss to Adjusted EBITDA
(unaudited)
| (amounts in thousands) | Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
| Net loss | $ | (71,790) | $ | (66,186) | $ | (174,370) | $ | (177,214) | |||||||||||||||
| Interest income | (1,618) | (2,640) | (2,121) | (4,408) | |||||||||||||||||||
| Interest expense | 19,208 | 13,674 | 31,990 | 22,964 | |||||||||||||||||||
| Changes in fair value of financial instruments | 17,870 | (12,000) | 50,203 | (936) | |||||||||||||||||||
| Other expense, net | 18,341 | 141 | 18,358 | 360 | |||||||||||||||||||
| Provision for income taxes | — | — | — | — | |||||||||||||||||||
| Depreciation and amortization expense | 6,409 | 11,610 | 13,454 | 29,315 | |||||||||||||||||||
| Stock-based compensation expense | 28,293 | 4,485 | 42,984 | 8,943 | |||||||||||||||||||
| Adjusted EBITDA | $ | 16,713 | $ | (50,916) | $ | (19,502) | $ | (120,976) | |||||||||||||||
Reconciliation of Net Cash Used in Operating Activities to Free Cash Flow
(unaudited)
(amounts in thousands) | Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
| Net cash provided by (used in) operating activities | $ | 7,288 | $ | (62,926) | $ | (24,050) | $ | (136,851) | |||||||||||||||
| Less: purchases of property and equipment | (1,386) | (2,588) | (4,075) | (4,326) | |||||||||||||||||||
| Free cash flow | $ | 5,902 | $ | (65,514) | $ | (28,125) | $ | (141,177) | |||||||||||||||